EmeritusDX Introduces Advanced 13-Color, 15-Parameter Flow Cytometry

NEWS PROVIDED BY
EmeritusDX
Oct 06, 2026, 14:45 ET

Higher-dimensional analysis delivers more diagnostic information from fewer tubes while supporting rapid, comprehensive hematologic evaluation

IRVINE, Calif., Oct. 6, 2026 /PRNewswire-PRWeb/ -- EmeritusDX, a CAP-accredited and CLIA-certified diagnostic laboratory, today announced the availability of advanced 13-color, 15-parameter flow cytometry, expanding its hematopathology capabilities and providing clinicians with a powerful tool for the diagnosis, classification, and monitoring of hematologic malignancies and disorders.

By evaluating multiple markers simultaneously within a single tube, EmeritusDX's 13-color, 15-parameter flow cytometry allows abnormal marker expression to be correlated to the same cellular population. This higher-dimensional approach provides greater diagnostic information while reducing the number of tubes required and helping characterize complex or heterogeneous cell populations.

"By capturing more information from fewer tubes, we can make better use of each patient specimen while giving physicians a more complete picture of complex cell populations."

Post this

More Answers from a Single Tube

Advanced multiparameter flow cytometry can evaluate lineage, clonality, cell maturity, and the coexpression of abnormal markers within a single acquisition. By providing a more complete picture of abnormal cellular populations, this approach supports comprehensive immunophenotypic characterization while making efficient use of limited or precious specimens.

Comprehensive immunophenotyping can also provide a strong preliminary disease classification after a single run, helping guide more targeted downstream testing and supporting a more efficient diagnostic workup.

The EmeritusDX 13-color, 15-parameter flow cytometry offering provides:

- Advanced multiparameter analysis for comprehensive immunophenotypic characterization
- More diagnostic information from fewer tubes, helping preserve valuable patient specimens
- Greater characterization of complex and heterogeneous cell populations
- Earlier preliminary disease classification to help guide targeted downstream testing
- Rapid turnaround, with approximately 90% of cases reported the same day they are received
- Direct access to board-certified hematopathologists for diagnostic consultation and case discussions
- Flexible partnership options, including full-service testing and Technical Component Flow Cytometry services

In addition to advanced technology, EmeritusDX combines rapid reporting with direct access to board-certified hematopathologists. Flow cytometry cases are reported the same day they are received, helping physicians receive timely diagnostic information to support patient care.

The EmeritusDX flow panel was developed by board-certified hematopathologists and experienced flow cytometry scientists with more than 60 years of combined expertise, bringing together advanced technology and specialized experience in hematologic diagnostics.

For laboratory and pathology partners, EmeritusDX also offers Technical Component Flow Cytometry services, allowing organizations to maintain professional interpretation in-house while leveraging EmeritusDX for high-quality specimen processing and data acquisition.

Advancing Hematologic Diagnostics

"Bringing 13-color, 15-parameter flow cytometry to EmeritusDX represents an important advancement in our hematopathology capabilities," said Robert Embree, CEO of EmeritusDX. "By capturing more information from fewer tubes, we can make better use of each patient specimen while giving physicians a more complete picture of complex cell populations. Combined with rapid turnaround and direct access to our hematopathologists, this technology strengthens our ability to deliver meaningful answers when they matter most." The addition of 13-color, 15-parameter flow cytometry reflects EmeritusDX's continued investment in advanced diagnostic technologies and its commitment to providing physicians with timely, actionable clinical information.

EmeritusDX offers a broad range of hematopathology services, including flow cytometry, molecular testing, cytogenetics, fluorescence in situ hybridization (FISH), and hematopathology consultation, allowing multiple diagnostic disciplines to work together to help answer complex clinical questions.

About EmeritusDX

EmeritusDX, part of Emeritus Medical Technology, is a cancer diagnostic and information company dedicated to patient care. Within its CAP-accredited and CLIA-certified laboratories, EmeritusDX provides advanced diagnostic testing and actionable clinical information to physicians and healthcare organizations. By addressing medical, scientific, and logistical challenges, EmeritusDX works to improve patient diagnosis, treatment, and care.

Together, We Save Lives.

Media Contact

Caitlin Buchanan, EmeritusDX, 1 800.959.2846, **CBuchanan@emeritusdx.com**, **https://emeritusdx.com/**

SOURCE EmeritusDX